Go Pro
→ Bank of America: 'Digital Dollar Inevitable' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$89.35
+1.6%		$84.10
$54.11
▼
$92.59
$33.72B1.423.30 million shs14.57 million shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$74.06
-0.1%		$80.07
$54.15
▼
$101.40
$9.95B0.951.22 million shs2.90 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$511.65
+1.0%		$550.37
$500.61
▼
$769.98
$40.31B1.54449,460 shs1.12 million shs
ResMed Inc. stock logo
RMD
ResMed
$225.35
-1.3%		$218.95
$180.26
▼
$284.87
$32.46B0.771.25 million shs3.82 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+7.61%-0.96%+23.29%+16.89%
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.00%-0.20%-13.55%-6.39%+31.92%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.00%+1.38%-6.27%-8.97%-20.16%
ResMed Inc. stock logo
RMD
ResMed
0.00%+3.24%-1.51%+19.34%-17.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$89.35
+1.6%		$84.10
$54.11
▼
$92.59
$33.72B1.423.30 million shs14.57 million shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$74.06
-0.1%		$80.07
$54.15
▼
$101.40
$9.95B0.951.22 million shs2.90 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$511.65
+1.0%		$550.37
$500.61
▼
$769.98
$40.31B1.54449,460 shs1.12 million shs
ResMed Inc. stock logo
RMD
ResMed
$225.35
-1.3%		$218.95
$180.26
▼
$284.87
$32.46B0.771.25 million shs3.82 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+7.61%-0.96%+23.29%+16.89%
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.00%-0.20%-13.55%-6.39%+31.92%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.00%+1.38%-6.27%-8.97%-20.16%
ResMed Inc. stock logo
RMD
ResMed
0.00%+3.24%-1.51%+19.34%-17.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.92
Moderate Buy$89.08-0.30% Downside
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.88
Moderate Buy$101.7737.41% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.60
Moderate Buy$747.0046.00% Upside
ResMed Inc. stock logo
RMD
ResMed
2.44
Hold$241.697.25% Upside

Current Analyst Ratings Breakdown

Latest GMED, IDXX, RMD, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$93.00 ➝ $102.00
9/18/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/18/2026
DexCom, Inc. stock logo
DXCM
DexCom
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
9/15/2026
ResMed Inc. stock logo
RMD
ResMed
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector Perform ➝ Outperform$244.00 ➝ $262.00
9/10/2026
ResMed Inc. stock logo
RMD
ResMed
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/31/2026
ResMed Inc. stock logo
RMD
ResMed
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$255.00 ➝ $267.00
8/27/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
8/19/2026
ResMed Inc. stock logo
RMD
ResMed
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$230.00
8/19/2026
ResMed Inc. stock logo
RMD
ResMed
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$230.00
8/11/2026
DexCom, Inc. stock logo
DXCM
DexCom
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/11/2026
ResMed Inc. stock logo
RMD
ResMed
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B7.23$2.77 per share32.27$7.04 per share12.69
Globus Medical, Inc. stock logo
GMED
Globus Medical
$2.94B3.38$6.28 per share11.79$33.86 per share2.19
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$4.30B9.37$15.08 per share33.92$20.10 per share25.46
ResMed Inc. stock logo
RMD
ResMed
$5.65B5.75$12.95 per share17.40$45.40 per share4.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5335.3229.011.5020.12%35.94%14.75%10/29/2026 (Estimated)
Globus Medical, Inc. stock logo
GMED
Globus Medical
$537.87M$3.9118.9413.741.1917.02%14.57%12.62%11/5/2026 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$1.06B$14.2235.9830.792.7325.03%71.96%33.60%11/2/2026 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.52B$10.4321.6117.221.4226.94%25.58%18.89%10/29/2026 (Estimated)

Latest GMED, IDXX, RMD, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.10$1.34+$0.24$1.10$782.88 million$789.61 million
8/6/2026Q4 2026
ResMed Inc. stock logo
RMD
ResMed
$2.89$2.95+$0.06$2.64$1.46 billion$1.46 billion
8/4/2026Q2 2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.94$4.27+$0.33$4.27$1.20 billion$1.22 billion
7/30/2026Q2 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6110$0.70+$0.0890$0.64$1.29 billion$1.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.641.17%+9.00%25.31%13 Years

Latest GMED, IDXX, RMD, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2026
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.661.15%8/20/20268/20/20269/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.47
1.73
1.43
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.62
2.93
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.19
1.17
0.87
ResMed Inc. stock logo
RMD
ResMed
0.06
3.10
2.42

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.38%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.79%
ResMed Inc. stock logo
RMD
ResMed
0.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000377.36 million376.30 millionOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
6,000134.26 million109.59 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00078.78 million78.16 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
11,370144.25 million143.31 millionOptionable

Recent News About These Companies

ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/resmed-inc-rmd-sleep-apnea-081836880.html
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
September 19 at 5:51 AM  |  insidermonkey.comhttps://www.insidermonkey.com/news/resmed-inc-rmds-sleep-apnea-leadership-supports-growth-despite-rising-competitive-pressures-1839115/
Nykredit A S Makes New Investment in ResMed Inc. $RMD
September 19 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-makes-new-investment-in-resmed-inc-rmd-2026-09-19/
Bank of America Corp DE Buys New Stake in ResMed Inc. $RMD
September 18 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-new-stake-in-resmed-inc-rmd-2026-09-18/
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?
September 16, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/margin-pressure-rising-costs-altering-171111986.html
ResMed stock heads into the open after a 4.5% Nasdaq gain
September 16, 2026  |  ad-hoc-news.deA
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
September 15, 2026  |  barrons.comhttps://www.barrons.com/articles/resmed-stock-rating-sleep-apnea-4665f675
Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946619-wall-street-lunch-ai-regulation-hopes-fade-after-trump-calls-ai-concerns-a-hoax
ResMed (NYSE:RMD) Trading 4.5% Higher - Here's What Happened
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-resmed-nyse-rmd-trading-45-higher-heres-what-happened-2026-09-15/
ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/resmed-projected-attain-high-single-150031615.html
ResMed upgraded at RBC Capital Markets on Q4 positives
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/resmed-upgraded-at-rbc-capital-markets-on-q4-positives/ar-AA2cgACo
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946562-resmed-inc-rmd-presents-at-morgan-stanley-24th-annual-global-healthcare-conference-transcript
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
September 15, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2989918/is-this-the-right-time-to-retain-resmed-stock-in-your-portfolio?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2989918
ResMed Inc. $RMD Shares Sold by Corient Private Wealth LP
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-resmed-inc-rmd-shares-sold-by-corient-private-wealth-lp-2026-09-15/
ResMed stock: Is RMD underperforming the healthcare sector?
September 14, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/resmed-stock-is-rmd-underperforming-the-healthcare-sector/ar-AA2cbR28
Tidal Investments LLC Increases Stake in ResMed Inc. $RMD
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tidal-investments-llc-increases-stake-in-resmed-inc-rmd-2026-09-14/
WINTON GROUP Ltd Makes New Investment in ResMed Inc. $RMD
September 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-winton-group-ltd-makes-new-investment-in-resmed-inc-rmd-2026-09-13/
National Pension Service Has $54.85 Million Stock Position in ResMed Inc. $RMD
September 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-national-pension-service-has-5485-million-stock-position-in-resmed-inc-rmd-2026-09-13/
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock
September 11, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-rmd-insider-buying-and-selling-2026-09-11/
ResMed CEO Michael Farrell Exercises Options and Sells Shares Under 10b5-1 Plan
September 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/resmed-ceo-michael-farrell-exercises-options-and-sells-shares-under-10b5-1-plan-2?utm_source=marketbeat.com&utm_medium=referral
ResMed: A Significant Upside Despite The Perceived Risk
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944925-resmed-stock-significant-upside-despite-perceived-risk

New MarketBeat Followers Over Time

Media Sentiment Over Time

DexCom stock logo

DexCom NASDAQ:DXCM

$89.35 +1.42 (+1.61%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$89.88 +0.53 (+0.59%)
As of 09/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Globus Medical stock logo

Globus Medical NYSE:GMED

$74.06 -0.10 (-0.13%)
Closing price 09/18/2026 03:59 PM Eastern
Extended Trading
$74.10 +0.04 (+0.06%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$511.65 +5.17 (+1.02%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$515.73 +4.08 (+0.80%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

ResMed stock logo

ResMed NYSE:RMD

$225.35 -3.07 (-1.34%)
Closing price 09/18/2026 03:59 PM Eastern
Extended Trading
$225.24 -0.11 (-0.05%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas